Date    : 2^nd October 2014

Venue : Education Centre, The Christie NHS Foundation Trust, Manchester

Course Description:

Delivered by: Elaine Vickers PhD, an expert speaker on targeted cancer therapies and Director of Science Communicated Ltd.

This course describes and explains the unique cellular and genetic features of haematological cancers and covers a diverse range of targeted treatments in the development of leukaemia, lymphoma and multiple myeloma. New approachces such as epigenetic modifiers and inhibitors of Bcl-2 and B-cell receptor signalling are introduced with the possibility of personalised treatment discussed.

Level: Advanced/Expert

Designed for doctors and senior oncology staff working in haematological cancers. Requires knowledge of immunology.

Topics Include

Key molecular concepts in leukaemia, lymphoma and myeloma

• Unique properties of myeloid and lymphoid cells.
• Common chromosome translocations and their consequences.
• Key genetic mutations & molecular pathways.

Targets and treatments for blood cancers

• Monoclonal antibody technology.
• Targeting cell surface (CD) antigens with monoclonal antibody treatments and their derivatives.
• Targeting over-active signalling pathways.
• Targeting the cell cycle.
• Targeting cell survival.
• Targeting epigenetics.

Specific Treatments

• Leukaemia: PML/RAR and BCR-ABL inhibitors.
• Lymphoma: ALK inhibitors.
• Myeloma: thalidomide and derivatives; targeting the tumour microenviroment; logical treatment combinations.

Fees:

Delegate fee: £100.00